

Supplementary Material

Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy

Chih-Lang Lin, MD^{1,2,3,†}; Szu-Yuan Wu, MD, MPH, PhD^{6,7,8,9,10,11,12,†,*}; Ming-Wei Lai, MD, PhD^{3,4,5}; Chao-Wei Hsu, MD^{3,4}; Wan-Ming Chen, PhD^{4,5}; An-Tzu Jao, BS⁶; Cheng-Hung Chien, MD^{1,2,3}; Ching-Chih Hu, MD, PhD^{1,3}; Rong-Nan Chien, MD^{3,4,*}; Chau-Ting Yeh, MD, PhD^{3,4,*}

Supplemental Table S1. Hepatocellular Carcinoma Risk Assessment Using PAGE-B Predictive Scoring System

CGMH Predictive Scoring	Group	HCC Risk	
		No HCC, N (%)	HCC, N (%)
0–9	Low risk	159 (100.00%)	0 (0.00%)
10–17	Moderate risk	398 (95.90%)	17 (4.10%)
≥18	High risk	200 (92.59%)	16 (7.41%)

Abbreviations: CGMH, Chang Gung Memorial Hospital; HCC, Hepatocellular carcinoma; N, number.